cial actions of SSRIs have proven challenging (1) , and the exact molecular targets necessary for the antianxiety and antidepressant actions of 5-HT remain unclear.
Nearly all 5-HT receptors belong to the G-proteincoupled receptor (GPCR) class of cell surface receptors and are, thus, subject to regulation by regulator of G-protein signaling (RGS) proteins, GTPase-activating proteins (GAPs) for G␣ subunits. By stabilizing the transition state in GTP hydrolysis by G␣, RGS proteins accelerate termination of GPCR signaling and limit the extent of the cellular response to GPCR stimulation (2) . Mice expressing a knock-in mutation in G␣ i2 rendering the protein insensitive to RGS protein-mediated regulation exhibit spontaneous anxiolytic and antidepressant behavior due to potentiation of 5-HT receptor 1A (5-HT 1A R) signaling (3) . The RGS protein superfamily contains some 30 members, and studies in G␣ i2 (G148S)-knock-in mice have failed to identify the specific RGS proteins responsible for anxiogenic and prodepressant blockade of 5-HT 1A Rs in vivo.
RGS6 belongs to the R7 subfamily of RGS proteins, characterized by their 3-domain structure. The RGS domain confers functional GAP activity directed toward G␣ i/o , and 2 additional domains, the disheveled, EGL-10, pleckstrin homology (DEP) and G␥-like (GGL) domains, control protein stability, localization, and protein-protein interactions. The GGL domain facilitates interaction between R7 family members and the atypical G␤ subunit G␤ 5 . Complex formation between R7 family members and G␤ 5 is required for the stable expression of both proteins (4) . Here we investigate the involvement of RGS6, expressed in hippocampus and cortex, in anxiety and depression behaviors in mice. We found that genetic ablation of RGS6 expression resulted in anxiolytic and antidepressant behavior by enhancing signaling through the 5-HT 1A R-adenylyl cyclase (AC) axis. Our results identify RGS6 as the primary regulator of 5-HT 1A R signaling and a principal modulator of anxiety and depression.
MATERIALS AND METHODS

Materials
WAY-100635, 8-hydroxy-2-(di-N-propylamino)tetralin (8-OH-DPAT), fluvoxamine, forskolin, and ␤-actin antibody were obtained from Sigma (St. Louis, MO, USA). SCH-50911 was from R&D Systems (Minneapolis, MN, USA). We developed the RGS6L and pan-RGS6 antibodies in rabbits. Antibodies to G␤ 5 and RGS7 were generously provided to us by Dr. Jason Chen (Virginia Commonwealth University, Richmond, VA, USA). Antibodies for protein kinase B (Akt), phospho-Akt (S473/T308), phospho-mitogen-activated protein kinase (MAPK), glycogen synthase kinase 3␤ (GSK3␤), phospho-GSK3␤(S9), phospho-PKA substrate, cyclic AMP (cAMP)-response element-binding protein (CREB), and phospho-CREB(S133) were from Cell Signaling Technology (Boston, MA, USA). 5-HT 1A R antibody and antibody for MAPK were from Santa Cruz Biotechnology (Dallas, TX, USA). Antibodies targeting microtubule-associated protein 2 (MAP2) and ␣-tubulin were from EMD Millipore (Billerica, MA, USA).
Mice
We generated RGS6 Ϫ/Ϫ mice as described previously (5) . Unless otherwise noted, experiments were performed with age-matched wild-type (WT; RGS6 ϩ/ϩ ), heterozygous (RGS6 ϩ/Ϫ ), and knockout (RGS6 Ϫ/Ϫ ) mice (10 -12 wk of age) backcrossed onto a C57BL6 background for 5 generations. Mice were housed on a 12-h light-dark cycle, and experiments were performed during the light cycle. Animals of both sexes were used for behavioral experiments, as we observed no sex-specific differences in mouse performance. Animals naive to each paradigm were used for all behavioral experiments. Drugs were administered 30 min prior to behavioral testing via intraperitoneal (i.p.) injection unless otherwise noted. For all animal experiments, analyses were performed by an observer blinded to mouse genotype and drug treatment. All animal experiments were performed in agreement with the U.S. National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Animal behavioral tests
Anxiety was assessed in mice placed in an automated 40.6-ϫ 40.6-ϫ 36.8-cm open field (San Diego Instruments; San Diego, CA, USA) for 30 min. Center activity was defined as the number of photobeam breaks occurring in the center (15.2ϫ15.2 cm) and expressed as a percentage of the total. Rearing was also monitored. The elevated plus maze apparatus has been described previously (6) . After placement of mice in the maze center, behavior was documented for 5 min and scored for total time spent in the open arms of the maze and the number of open arm entries. Novelty-induced hypophagic behavior was assessed in nonstarved animals placed in home or novel cage environments, as outlined previously (7) . Latency to drink and total volume consumed were measured. In the marble-burying test, mice were placed in a clear polycarbonate box (18ϫ28ϫ13 cm) containing 5 cm of bedding with 15 marbles arranged in a 5 ϫ 3 grid. The total number of glass marbles buried (covered by 2/3 or more) during a 30-min testing period was assessed. For the forced-swim test, animals first underwent a 15-min preswim in a glass cylinder (18 cm diameter) in ϳ10 cm of 25°C water. On a subsequent testing day, behavior was videotaped for 10 min and scored for immobility, climbing, and swimming. Finally, in the tail-suspension test, individual mice were suspended by the tail using adhesive tape from a plastic bar (30-cm elevation) enclosed on all but one side (8) . Behavior was videotaped for 5 min, and videos were scored for total immobility time.
Acute measurements of core body temperature
At 5 d before drug injection, mice were individually housed and initially habituated by measurement of core body temperature using a rodent rectal probe (Physitemp Instruments, Clifton, NJ, USA). On the day of testing, core body temperature was measured 30 min after administration of indicated doses of 8-OH-DPAT (3, 9) .
Cortical neuron isolation and culture
Cultures of dissociated cortical neurons from 1-d-old mouse pups were isolated as described previously (10) . Briefly, the prefrontal cortex was dissected from P1 mouse pups, washed with HBSS, and then digested in 0.05% trypsin-EDTA (Life Technologies, Carlsbad, CA, USA) for 10 min at 37°C. Tissue was washed and resuspended in complete neurobasal medium (Life Technologies) supplemented with 2 mM glu-tamine and B27, and cells were dissociated by repeated pipetting. Neurons were plated onto tissue culture dishes coated with poly-l-lysine (Sigma) and laminin, and the medium was replaced after 12 h. After 1 d in culture, neurons were treated with forskolin (50 M, 15 min) followed by 8-OH-DPAT (1 M, 15 min) and were processed for immunoblotting.
cAMP measurements
Isolated WT and RGS6
Ϫ/Ϫ cortical neurons were first cultured in DMEM containing 1% bovine serum albumin (BSA) and 500 M 3-isobutyl-1-methylxanthine (IMBX). After 20 min, cells were treated with and without forskolin (50 M, 5 min), concurrent with 8-OH-DPAT (1 M, 6 min) where indicated. Reactions were terminated by liquid nitrogen addition directly to the culture dishes. cAMP measurements were performed with the Direct cAMP ELISA kit (Enzo Life Sciences, Farmingdale, NY, USA), according to the manufacturer's protocol.
Immunoblotting
Whole hippocampi, dorsal striatum, and prefrontal cortex were rapidly dissected from WT and RGS6 Ϫ/Ϫ mice following drug treatment, where indicated, and flash-frozen in liquid nitrogen. Tissue homogenates and cell lysates were prepared in radioimmunoprecipitation assay (RIPA) buffer containing protease and phosphatase inhibitors (Sigma), quantified, and probed as previously described (11) . Protein (20 g/sample) was subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting using standard techniques. Immunoblots were visualized using the Odyssey Imaging System with appropriate fluorescently labeled secondary antibodies (LI-COR Biosciences; Lincoln, NE, USA). Densitometric quantification of Western blots was performed utilizing ImageJ software (U.S. National Institutes of Health, Bethesda, MD, USA), and expression of indicated proteins was normalized to actin or ␣-tubulin-loading controls or total protein levels (phosphorylated proteins) and expressed relative to control conditions.
Immunohistochemistry
Formaldehyde (4%)-perfused frozen brain sections from WT and RGS6 Ϫ/Ϫ mice were processed to examine protein expression and localization. Briefly, cryosections were washed in phosphate-buffered saline (PBS), blocked with 5% BSA, and incubated overnight at 4°C with and without (control) indicated antibodies. Following washing 4 times in PBS (10 min each), sections were incubated for 1 h at room temperature with Alexa Fluor secondary antibodies (Life Technologies). Sections were visualized using confocal microscopy, as described previously (5) .
Statistical analysis
Data were analyzed by Student's t test or 2-way analysis of variance (ANOVA) with the Bonferroni post hoc adjustment as appropriate. Statistical analyses were performed using Prism software (GraphPad Software; La Jolla, CA, USA). Results were considered significantly different at values of P Ͻ 0.05. Values are expressed as means Ϯ sem.
RESULTS
Serotonergic deficits in brain regions comprising the cortico-limbic-striatal neuronal circuit have been implicated in anxiety and depression. We detected expression of multiple RGS6 isoforms in hippocampus and cerebral cortex of WT mice that were absent in RGS6 Ϫ/Ϫ mice. The R7 family member RGS7 also exhibits robust expression in these tissues and likely contributes to the stabilization of G␤ 5 in the absence of RGS6 (Fig. 1A) . Immunohistochemical staining of brain sections confirmed our Western blot analysis results, showing specific expression of RGS6 in prefrontal cortex and the dentate gyrus (DG), cornu ammonis 3 (CA3), and CA1 regions of the hippocampus (Fig.  1B) . To confirm neuron-specific RGS6 localization, we costained sections with the somatodendritic neuronal marker MAP2. RGS6 and MAP2 exhibit identical expression patterns in hippocampus and cortex, confirming RGS6 localization in hippocampal (CA3/CA1) and cortical pyramidal neurons (Fig. 1C) . In the DG, RGS6 expression appears most prominent in the granule cell layer (Fig. 1C) , a pattern we also observed in cerebellum (11). On the basis of these results, we hypothesized that loss of RGS6-dependent G␣ i/o GAP activity might contribute to the anxiolytic and antidepressant phenotype observed in mice harboring the G␣ i2 (G148S) mutation. Therefore, we observed the performance of our RGS6 Ϫ/Ϫ mice in behavior paradigms used to quantitate rodent anxiety and depression-related behaviors. The open-field test is used to assess rodent response to stress from social isolation and novel environment, while simultaneously measuring locomotor activity.
RGS6
Ϫ/Ϫ mice exhibit mild hyperactivity ( Fig. 2A) , but no difference in anxiety-related behaviors, including time spent in the center of the field (Fig. 2B) or rearing (Fig. 2C) . A similar lack of anxiolytic behavior in this test was observed in RGS-insensitive G␣ i2 -knock-in mice, and, while they exhibited no increase in acute locomotor activity (3), these mice do display increased activity in the home cage (12) . Conversely, RGS6 Ϫ/Ϫ mice exhibit no hyperactivity in the home cage (unpublished data), indicating that the increased activity in the open field is likely a response to the novel environment.
In the elevated plus maze, which exploits the approach-avoidance conflict in rodents, RGS6 Ϫ/Ϫ mice exhibit a remarkable reduction in anxiety, spending more time in the open arms ( Fig. 2D ) and displaying a greater number of open-arm entries (Fig. 2E ). Similarly, while no difference was observed in the home cage, mice lacking RGS6 show a reduced hyponeophagic response in a novel cage (Fig. 2F ). RGS6 Ϫ/Ϫ animals also consumed a larger volume of sweetened solution in both cages (Fig. 2G ), an effect seen in mice treated chronically with SSRIs (7). Consistent with a reduction in anxiety, RGS6 Ϫ/Ϫ mice buried fewer marbles in the marble-burying test, an approximation of obsessive compulsive disorder (OCD)-related anxiety (Fig. 2H) . Depression-like behavior is assessed in rodents using models of behavioral despair, including the forced-swim and tail-suspension tests. Indeed, RGS6 Ϫ/Ϫ mice show reduced immobility and climbing behavior with a concomitant increase in swimming in the forcedswim test (Fig. 2I) . Interestingly, RGS6 Ϫ/Ϫ mice completely phenocopy G␣ i2 (G148S) mice, leading us to hypothesize that this phenotype results from loss of RGS6-mediated inhibition of G-protein signaling.
Treatment with WAY-100635, a 5-HT 1A R antagonist, rapidly reversed the antidepressant phenotype of RGS6 Ϫ/Ϫ mice in the tail-suspension test (Fig. 3A) , as well as the anxiolytic phenotype of RGS6 Ϫ/Ϫ mice in the elevated plus maze (Fig. 3B, C) . Thus, loss of RGS6 promotes anxiolytic and antidepressant behaviors by enhancing 5-HT 1A R-dependent signaling. In contrast, blockade of GABA B receptors (GABA B Rs), G␣ i/o -coupled GPCRs implicated in RGS6-dependent motor coordination (11), with antagonist SCH-50911 failed to affect performance of mice in the elevated plus maze, regardless of genotype (Fig, 3B, C) . SCH-50911 reverses the ataxic phenotype of RGS6 Ϫ/Ϫ mice (11). This result demonstrates that the mild ataxia observed in RGS6 Ϫ/Ϫ mice (11) likely does not contribute to their performance. Furthermore, in the novelty-induced hyponeophagia test, WAY-100635 treatment also restored the aberrant latency to drink (Fig. 3D ) and solution consumption in the novel cage (Fig. 3E ) observed in RGS6 Ϫ/Ϫ mice to levels comparable to those observed in WT mice. Thus, the reduced latency to drink and increased solution consumption seen as a consequence of RGS6 deficiency in this test also results from potentiation of 5-HT 1A R signaling. Each of the paradigms described can be used in rodents to screen antidepressant and antianxiety medications for predictive efficacy in human patients. Given our findings, we examined whether loss of RGS6 increases the sensitivity of mice to drugs targeting 5-HT 1A Rs. For these experiments WT, RGS6 ϩ/Ϫ , and RGS6 Ϫ/Ϫ mice were challenged with a dose of the SSRI fluvoxamine or direct 5-HT 1A R agonist 8-OH-DPAT insufficient to provoke antidepressant effects in WT mice. Treatment with either fluvoxamine or 8-OH-DPAT failed to provoke antidepressant effects in WT mice and had no additional antidepressant effects in RGS6 Ϫ/Ϫ mice (Fig. 3F) , the latter possibly due to a maximal antidepressant phenotype in these mice. In contrast, RGS6 ϩ/Ϫ mice, while showing no phenotypic difference from WT mice, were dramatically sensitized to the actions of both drugs (Fig. 3F) . In fact, submaximal doses of both drugs decreased immobility of RGS6 ϩ/Ϫ mice to levels observed in RGS6 Ϫ/Ϫ mice (Fig.  3F) . Conversely, the hypothermic response to 8-OH-DPAT, solely mediated by 5-HT 1A autoreceptors in the raphe nucleus (13), occurred with equal potency and efficacy in all mice regardless of genotype (Fig. 3G) . Taken together, these results indicate that RGS6 has powerful anxiogenic and prodepressant actions through its ability to terminate postsynaptic 5-HT 1A R signaling.
We next sought to determine the molecular basis for the anxiolytic phenotype of RGS6 Ϫ/Ϫ mice. Like RGS6, 5-HT 1A heteroreceptors are located in the soma and dendrites of hippocampal and cortical neurons (14) . No difference in 5-HT 1A R expression levels was observed in RGS6 Ϫ/Ϫ tissue, indicating that the phenotype of RGS6 Ϫ/Ϫ mice is not due to receptor upregulation (Fig. 4A) . In brain, 5-HT 1A R stimulation activates an array of downstream signaling, including G␤␥-mediated, phosphorylation-dependent activation of GSK3␤, Akt, and MAPK and G␣ i -mediated inhibition of the AC-cAMP-PKA signaling axis (15) . Contrary to results obtained in G␣ i2 (G148S)-knock-in mice (3), no difference in GSK3␤ phosphorylation (Fig. 4A) was detected comparing WT and RGS6 Ϫ/Ϫ tissue lysates from the cortex (Fig. 4B), hippocampus (Fig. 4C ), or striatum (Fig. 4D) . Similarly, no genotype-dependent changes in the levels of phosphorylated MAPK or Akt were seen (Supplemental Fig. S1 ). These results show that the anxiolytic and antidepressant phenotype of RGS6 Ϫ/Ϫ mice is not associated with enhanced G␤␥-mediated signaling by the 5-HT 1A R. In contrast, despite considerable heterogeneity in individual responses, we observed a 5-HT 1A R-dependent reduction in hippocampal and cortical phospho-CREB levels in RGS6 Ϫ/Ϫ animals that did not occur in the striatum, where 5-HT 1A Rs are not expressed (Fig. 4) . In the cortex, PKA activity, as measured by immunoreactivity of an antibody recognizing the phosphorylated PKA substrate motif (RRXT/S-P), was also reduced in RGS6 Ϫ/Ϫ tissue lysates, an effect reversible by 5-HT 1A R blockade (Fig. 4B) . These findings suggest that loss of RGS6 promotes 5-HT 1A R/G␣ imediated inhibition of the AC-cAMP-PKA axis.
Our in vivo data were recapitulated in cortical neurons isolated from WT and RGS6 Ϫ/Ϫ mice. Interestingly, serum-induced phospho-CREB levels were markedly lower in cortical neurons isolated from RGS6 Ϫ/Ϫ mice compared to their WT counterparts (Fig. 5A, B) , possibly reflecting perpetuation of the in vivo phenotype in culture. Forskolin, a direct AC activator, resulted in robust CREB activation in RGS6 Ϫ/Ϫ cortical neurons, an effect not observed in WT neurons. This suggests that increased G␣ i activity and consequent reduced AC activity underlies the lower level of CREB phosphorylation in RGS6 Ϫ/Ϫ neurons. Furthermore, RGS6 Ϫ/Ϫ neurons were remarkably sensitized to inhibition of CREB phosphorylation induced by 8-OH-DPAT, whereas 8-OH-DPAT had no effect on CREB phosphorylation in WT cells (Fig. 5B ). To confirm a direct effect of RGS6 knockout on AC activity, we also measured forskolin-stimulated cAMP accumulation in 8-OH-DPAT-treated WT and RGS6 Ϫ/Ϫ cortical neurons. Forskolin treatment resulted in cAMP generation in cells of both genotypes (Fig. 5C) ; however, RGS6 Ϫ/Ϫ Figure 4 . RGS6 Ϫ/Ϫ mice exhibit potentiation of 5-HT 1A R/G␣ i -dependent signaling in hippocampus and cortex. A) RGS6, 5-HT 1A R, actin, phosphototal GSK3␤, and phospho-CREB, total CREB, and phospho-PKA substrate immunoblots from WT and RGS6 Ϫ/Ϫ mice treated with and without the 5-HT 1A R antagonist WAY-100635 (WAY; 0.1 mg/kg s.c.). Data are presented in triplicate for all experimental conditions. B-D) Densitometric quantification of phospho-GSK3␤, phospho-CREB, and PKA substrate phosphorylation immunoblots was performed in cortex (B), hippocampus (C), and striatum (D) (nϭ3-6). There was no effect of genotype or drug treatment on phospho-GSK3␤ levels in hippocampus or cortex. Two-way ANOVA revealed a significant effect of genotype on phospho-CREB levels in cortex (F 1,20 ϭ7.78; Pϭ0.0113) and hippocampus (F 1,20 ϭ5.12; Pϭ0.035). There was also a significant effect of genotype (F 1,8 ϭ10.46; Pϭ 0.0120) on phospho-PKA substate immunoreactivity in cortex but not hippocampus. Neither genotype nor drug treatment affected phosphorylated protein levels in striatum. Data are presented as means Ϯ sem. *P Ͻ 0.05, **P Ͻ 0.01. cells exhibited a more robust inhibition of cAMP accumulation in response to 8-OH-DPAT (Fig. 5C) . These results illustrate the remarkable sensitivity of RGS6 Ϫ/Ϫ cells to 5-HT 1A R stimulation. Together, our findings indicate that RGS6 is a critical negative regulator of signaling through G␣ i -coupled 5-HT 1A heteroreceptors in brain and isolated neurons and suggest that potentiation of 5-HT 1A R-mediated AC inhibition might underlie the antidepressant phenotype of mice lacking RGS6.
In fact, direct AC activation using forskolin was sufficient to completely reverse the reduced immobility of RGS6 Ϫ/Ϫ mice in the tail-suspension test (Fig. 6A) , indicating that G␣ i -mediated inhibition of AC is exclusively responsible for reducing depression in RGS6 Ϫ/Ϫ animals. As expected, on the basis of its ability to stimulate cAMP production and subsequent PKA activity, forskolin treatment resulted in elevated levels of phospho-CREB in the hippocampus and cortex (Fig.  6B, C) and PKA substrate phosphorylation in cortex and striatum (Fig. 6C, D) . Notably, the reductions in both CREB and PKA substrate phosphorylation seen in RGS6 Ϫ/Ϫ tissue lysates were normalized to WT levels ( Fig. 6B-D) , highlighting the potential importance of PKA effectors in the anxiolytic and antidepressant phenotype resulting from RGS6 loss. Thus, we propose a model whereby RGS6 counteracts the anxiolytic and antidepressant actions of 5-HT through blockade of postsynaptic 5-HT 1A R-dependent AC inhibition, leading to increases in cAMP and activation of downstream AC effectors, including PKA and CREB (Fig. 7) .
DISCUSSION
Here, we identify RGS6 as a critical regulator of 5-HT 1A R-and AC-dependent anxiolytic and antidepressant actions. RGS6 expression is enriched in hippocampal and cortical neuron populations, 5-HT 1A R-expressing cells implicated in multiple mood disorders (14, 15) , and loss of RGS6 potentiates 5-HT 1A R-G␣ i -dependent AC inhibition in vivo and in isolated cortical neurons. RGS6 Ϫ/Ϫ mice exhibit a spontaneous anxiolytic and antidepressant phenotype in multiple behavioral paradigms, including tests affected only by chronic antidepressant treatment. While the phenotype of RGS6 heterozygotes is indistinguishable from WT mice, partial RGS6 deficiency elicits a remarkable sensitization to the antidepressant actions of the SSRI fluvoxamine and 5-HT 1A R agonist 8-OH-DPAT. These data suggest that partial loss or inhibition of RGS6 is sufficient to potentiate the actions of serotonergic drugs. Indeed, our results indicate that under physiological conditions, a single copy of the RGS6 gene is sufficient to completely prevent 5-HT-mediated signaling through postsynaptic 5-HT 1A Rs. Furthermore, RGS6 Ϫ/Ϫ mice exhibit a level of anxiety comparable to that of WT mice treated chronically with therapeutic Ϫ/Ϫ mice treated with and without forskolin (7.5 mg/kg, 45 min). Data are presented in triplicate for all experimental conditions. C-E) Densitometric quantification (nϭ3) of phospho-CREB, and PKA substrate phosphorylation immunoblots was performed in cortex (C), hippocampus (D), and striatum (E). In cortex, 2-way ANOVA revealed a significant effect of genotype (F 1,8 ϭ12.95, Pϭ 0.007; F 1,8 ϭ13.38, Pϭ0.0065) and drug treatment (F 1,8 ϭ79.50, PϽ0.0001; F 1,8 ϭ106.28, PϽ0 .0001) on phospho-CREB and phospho-PKA substrate levels, respectively. There was also a significant effect of genotype (F 1,8 ϭ14.78; Pϭ0.0049) and drug treatment (F 1,8 ϭ99.51; PϽ0.0001) on phospho-CREB in hippocampus, but no difference in PKA-substrate immunoreactivity. Genotype did not affect phosphorylated protein levels in striatum, but there was a significant effect of drug on PKA substrate phosphorylation (F 1,8 ϭ73.40; PϽ0.0001 ). Data are presented as means Ϯ sem. *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001 vs. WT;
doses of SSRIs. Unlike G␣ i2 (G148S) mutant mice (12), RGS6 loss has no detrimental effects on mouse fertility, development, or body weight, making RGS6 an attractive novel drug target. The antidepressant phenotype of RGS6 Ϫ/Ϫ animals is rapidly and completely reversible by 5-HT 1A R blockade. 5-HT 1A R expression is reduced in critical brain regions of patients with depression, and polymorphisms in the 5-HT 1A R gene are associated with disease susceptibility and serotonergic therapy responsiveness (16) . Presynaptic 5-HT 1A autoreceptors located in the raphe nucleus promote anxiety by inhibiting 5-HT release. Conversely, 5-HT 1A heteroreceptors activate diverse signaling in postsynaptic neurons located in both hippocampus and cortex and are believed to mediate the antidepressant and antianxiety actions of 5-HT (14, 17) . Our data strongly suggest that RGS6 is primarily responsible for regulation of postsynaptic 5-HT 1A heteroreceptors. First, RGS6 heterozygotes are sensitized to the antidepressant actions of 5-HT 1A R stimulation, but 8-OH-DPAT induced hypothermia, an effect dependent on autoreceptor action (13) , occurs with equal potency in RGS6 ϩ/Ϫ and WT mice. Second, only 5-HT 1A heteroreceptors couple to G␣ i and induce inhibition of AC (18), and the antidepressant phenotype of RGS6 Ϫ/Ϫ mice is completely dependent on AC inhibition, as it is completely reversed by forskolin. Finally, the robust reduction in anxiety and depression-related behaviors in mice lacking RGS6 is consistent with potentiation of postsynaptic receptor signaling rather than enhanced inhibition of 5-HT release, which would be expected to increase rather than decrease these behaviors.
Studies in knockout mice have identified 5-HT 1A Rs as critical determinants of both baseline anxiety and responsiveness to SSRI therapy, actions due primarily to receptor function during early development (13, 19, 20) . However, these observations do not preclude a role for 5-HT 1A R signaling in controlling anxiety and depression in adult animals, especially given extensive historical evidence that hyperactivation of 5-HT 1A heteroreceptors in adult mice produces anxiolytic and antidepressant effects (21) (22) (23) . Our results demonstrate that singular loss of RGS6-mediated 5-HT 1A R inhibition is sufficient to maximize the antidepressant and anxiolytic capacity of 5-HT 1A R signaling in response to endogenous 5-HT. Thus, RGS6 functions as a critical countermeasure against the antianxiety and antidepressant actions of 5-HT and serotoninergic drugs. While it is possible that RGS6 deletion leads to alterations in development of the circuitry underlying anxiety and depression-related behaviors, two of the observations render this supposition unlikely. First, the antidepressant and anxiolytic phenotype in RGS6 Ϫ/Ϫ mice is rapidly and completely reversible through 5-HT 1A R blockade. Second, despite the lack of differences in anxiety or depression behaviors in RGS6 heterozygous mice under basal conditions, RGS6 ϩ/Ϫ mice are greatly sensitized to subefficacious doses of 5-HT 1A R-targeted drugs.
Previous work in mice expressing RGS-insensitive G␣ i2 demonstrated that endogenous RGS proteins block 5-HT 1A R-mediated GSK3␤ phosphorylation (3) . Given studies identifying GSK3␤ as an important molecular target of 5-HT (24) , it was postulated that increased GSK3␤ phosphorylation contributed to the anxiolytic phenotype of G␣ i2 (G148S) mutants. RGS6 Ϫ/Ϫ mice show an identical phenotype in the absence of increased phospho-GSK3␤, suggesting that GSK3␤ inactivation does not cause the antidepressant phenotype resulting from loss of RGS protein regulation. Instead, RGS6 appears to selectively regulate a specific 5-HT 1A Reffector pathway, namely the G␣ i -AC-PKA-CREB axis, without affecting other targets (e.g., GSK3␤). Indeed, the ability of forskolin to reverse the antidepressant phenotype of RGS6 Ϫ/Ϫ mice suggests that G␤␥ effectors (GSK3␤, MAPK, Akt) are dispensable for the ability of 5-HT 1A Rs to reduce depression.
Although our results demonstrate that AC inhibition is clearly an important and essential consequence of 5-HT 1A heteroreceptor activation in reducing anxiety and depression, the exact molecular determinant of this response remains unclear. We demonstrate a clear decrease in PKA substrate phosphorylation in the cortex, and levels of phosphorylated CREB in both the cortex and hippocampus of RGS6 Ϫ/Ϫ mice that is normalized following 5-HT 1A R blockade or AC activation. However, numerous signaling moieties are mobilized on AC activation, including cyclic nucleotidegated ion channels and PKA and its substrates, which may number in the hundreds or even thousands in mammals (25) . Because of its ability to promote hippocampal neurogenesis believed to contribute to SSRI efficacy (20) , the role of CREB in anxiety and depression has been explored but remains controversial, as CREB appears to have prodepressant or antidepressant actions depending on the neuronal population investigated (26, 27) . It is important to note that, although forskolin treatment caused a clear increase in phospho-CREB in the hippocampus and cortex, this ϳ2-fold increase was insufficient to alter the behavioral phenotype of WT animals. It seems likely, therefore, that increases in CREB activity may alleviate anxiety and depression only after prolonged stimulation, consistent with the necessity for long-term changes in neuronal architecture. In future studies, RGS6 Ϫ/Ϫ mice represent a useful model system to further delineate the molecular signaling cascades responsible for the antianxiety and antidepressant actions resulting from 5-HT 1A R-mediated inhibition of AC.
Despite the fact that other R7 RGS protein family members, including RGS7, are also expressed in hippocampus and cortex, our results clearly demonstrate that they fail to compensate for the loss of RGS6-mediated regulation of the 5-HT 1A heteroreceptor-G␣ i -AC signaling axis. Our observations do not, however, completely rule out a role for other members of the R7 RGS protein family, which includes RGS6, RGS7, RGS9, and RGS11, in anxiety, depression, and the actions of serotoninergic drugs. Indeed, polymorphisms in the RGS7 gene are associated with panic disorder subtypes and gender-biased disease susceptibility (28) . However, RGS7 is unable to regulate 5-HT 1A R-mediated inhibition of AC in vitro (29) , indicating that RGS7 may affect this anxiety-related behavior through regulation of a different receptor signaling cascade. Mice lacking RGS9 exhibit no changes in anxiety, though their behavior has only been evaluated in the open-field test (30) . Because mice lacking RGS7 or RGS11 have not been evaluated in the behavioral paradigms described in this work, it is unknown whether these R7 family members have any role in modulating anxiety and depression. Our work clearly demonstrates that RGS6 is a critical regulator of 5-HTmediated antianxiety and antidepressant actions through its ability to inhibit G␣ i -coupled 5-HT 1A Rs.
It is also likely that RGS6 is not the sole regulator of 5-HT 1A R signaling in brain. Indeed, deficiency in the RGS2 gene, implicated in human anxiety disorders (31, 32) , promotes anxiety and depression-related behaviors in mice by affecting expression and/or activity of 5-HT 1A autoreceptors (33) (34) (35) . In vivo, RGS4 overexpression inhibits 5-HT 1A autoreceptors (36) , and RGS4 inhibition in cortical neurons potentiates 5-HT 1A R signaling (37) . These studies demonstrate nondiscriminate and opposing actions of RGS4 on presynaptic and postsynaptic 5-HT 1A Rs. In addition, RGS4 also regulates G␣ q -coupled 5-HT receptors (29) , known to promote anxiety. Together, these results make predictions regarding effects of RGS4 inhibition on net behavioral outputs challenging. Recent evidence suggests that while RGS4-knockout mice exhibit no baseline difference in anxiety or depression-related behaviors, RGS4 up-regulation in the nucleus accumbens may be important in the acute and chronic actions of antidepressants (38) . Thus, different RGS proteins appear to regulate 5-HT 1A R populations in distinct temporal, contextual and spatial manners. RGS6 is the first RGS protein identified that appears to selectively modulate 5-HT 1A heteroreceptor populations in vivo, although the exact mechanisms contributing to this heteroreceptor specificity remain unknown.
In summary, our results demonstrate that RGS6 deletion selectively enhances the actions of endogenous 5-HT at postsynaptic 5-HT 1A heteroreceptors, believed to underlie the beneficial effects of serotonergic drugs, leading to spontaneous anxiolytic and antidepressant behavior. Although the exact downstream molecular determinant of antidepressant phenotype of RGS6 Ϫ/Ϫ mice remains unclear, signaling cascades classically activated by the G␤␥ subunit of the heterotrimeric G-protein complex appear to be dispensable, and, instead, G␣ i -mediated inhibition of AC is required. In short, RGS6 functions as the gatekeeper for 5-HT-mediated anxiolytic and antidepressant actions due primarily to its ability to completely block 5-HT 1A Rmediated inhibition of AC.
